Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Quality assessment of autografting by probability evaluation: model estimation by clinical end-points in newly diagnosed multiple myeloma patients

Roer, O ; Hammerstrom, J ; Lenhoff, Stig LU ; Mylin, AK ; Knudsen, LM ; Rasmussen, T and Johnsen, HE (2006) In Cytotherapy 8(1). p.79-88
Abstract
Background Pre-transplant clinical evaluation of autografting is an important step in predicting post-transplant support, complications and safety. Today, unfavorable outcomes such as early death or graft failure are rare, making them unsuitable for quality assessment of supportive autografting. However, end-points constructed from frequently occurring clinical events may estimate clinically relevant prognostic models. Methods The present retrospective analysis was based on two consecutive clinical trials in the Nordic area, including up to 640 newly diagnosed multiple myeloma patients. Results In the model, the efficacy (time on antibiotics and use of transfusions) was influenced by pre-transplant variables, including sex, nationality,... (More)
Background Pre-transplant clinical evaluation of autografting is an important step in predicting post-transplant support, complications and safety. Today, unfavorable outcomes such as early death or graft failure are rare, making them unsuitable for quality assessment of supportive autografting. However, end-points constructed from frequently occurring clinical events may estimate clinically relevant prognostic models. Methods The present retrospective analysis was based on two consecutive clinical trials in the Nordic area, including up to 640 newly diagnosed multiple myeloma patients. Results In the model, the efficacy (time on antibiotics and use of transfusions) was influenced by pre-transplant variables, including sex, nationality, serum creatinine, hemoglobin, disease stage at diagnosis, response following induction therapy, length of priming and average graft CD34(+) cell number per day of harvest. The toxicity end-point (time to blood cell recovery) was influenced by nationality, marrow plasma cell percentage, serum creatinine, M-component isotype, response to induction therapy, length of priming and graft CD34(+) cell number. The safety (early disease recurrence or death) was influenced by serum creatinine, hemoglobin, treatment response and CD34(+) cell number. Discussion In conclusion, the model illustrates that intervention strategies in quality assessment of autografting may benefit from probability estimates of graded clinical end-points. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
translational, research, quality assessment, autografting, multiple myeloma
in
Cytotherapy
volume
8
issue
1
pages
79 - 88
publisher
Taylor & Francis
external identifiers
  • pmid:16637135
  • wos:000235427100010
  • scopus:33344460815
ISSN
1477-2566
DOI
10.1080/14653240500499549
language
English
LU publication?
yes
id
ec394a86-acfe-460a-a15f-bc06a1050f4b (old id 417535)
date added to LUP
2016-04-01 12:19:00
date last changed
2021-06-30 05:34:59
@article{ec394a86-acfe-460a-a15f-bc06a1050f4b,
  abstract     = {Background Pre-transplant clinical evaluation of autografting is an important step in predicting post-transplant support, complications and safety. Today, unfavorable outcomes such as early death or graft failure are rare, making them unsuitable for quality assessment of supportive autografting. However, end-points constructed from frequently occurring clinical events may estimate clinically relevant prognostic models. Methods The present retrospective analysis was based on two consecutive clinical trials in the Nordic area, including up to 640 newly diagnosed multiple myeloma patients. Results In the model, the efficacy (time on antibiotics and use of transfusions) was influenced by pre-transplant variables, including sex, nationality, serum creatinine, hemoglobin, disease stage at diagnosis, response following induction therapy, length of priming and average graft CD34(+) cell number per day of harvest. The toxicity end-point (time to blood cell recovery) was influenced by nationality, marrow plasma cell percentage, serum creatinine, M-component isotype, response to induction therapy, length of priming and graft CD34(+) cell number. The safety (early disease recurrence or death) was influenced by serum creatinine, hemoglobin, treatment response and CD34(+) cell number. Discussion In conclusion, the model illustrates that intervention strategies in quality assessment of autografting may benefit from probability estimates of graded clinical end-points.},
  author       = {Roer, O and Hammerstrom, J and Lenhoff, Stig and Mylin, AK and Knudsen, LM and Rasmussen, T and Johnsen, HE},
  issn         = {1477-2566},
  language     = {eng},
  number       = {1},
  pages        = {79--88},
  publisher    = {Taylor & Francis},
  series       = {Cytotherapy},
  title        = {Quality assessment of autografting by probability evaluation: model estimation by clinical end-points in newly diagnosed multiple myeloma patients},
  url          = {http://dx.doi.org/10.1080/14653240500499549},
  doi          = {10.1080/14653240500499549},
  volume       = {8},
  year         = {2006},
}